1. Adams RD, Victor M, Ropper AH. Principles of Neurology. 6 th ed. New York, NY: McGraw-Hill; 1997:1067-1078.
2. James Parkinson. An essay on the shaking palsy. 1817. Neuropsychiatry Clin Neurosci. Spring 2002;14(2):223-36.
3. Capriotti T, Terzakis K. Parkinson Disease. Home Healthc Now.
2016;34(6):300-7.
4. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol.2006;5(3):235-45.
5. J.A. Obeso, M. Stamelou, C.G. Goetz, W. Poewe, A.E. Lang, D. Weintraub, D.
Burn, G.M. Halliday, E. Bezard, S.Przedborski, S. Lehericy, D.J. Brooks, J.C.
Rothwell, M. Hallett, M.R. DeLong, C. Marras, C.M. Tanner, G.W. Ross, J.W.
Langston, C. Klein, V. Bonifati, J. Jankovic, A.M. Lozano, G. Deuschl, H.
Bergman, E. Tolosa, M. Rodriguez-Violante, S. Fahn, R.B. Postuma, D. Berg, K.
Marek, D.G. Standaert, D.J. Surmeier, C.W. Olanow, J.H. Kordower, P. Calabresi, A.H.V. Schapira, A.J. Stoessl. Past, Present, and Future of Parkinson’s Disease: A Special Essay on the 200th Anniversary of the Shaking Palsy.Mov Disord.
2017;32(9):1264-1310.
6. Wong SL, Gilmour H, Ramage-Morin PL. Parkinson's disease: Prevalence, diagnosis and impact. Health Rep. 2014;25(11):10-4.
7. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-76.
8. Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912.
9. Poewe W. Non-motor symptoms in Parkinson‟s disease. In: Jankovic J, Tolosa E, editors. Parkinson‟s Disease and Movement Disorders. Philadelphia: Lippincott Williams & Wilkins. 2007;67-76.
10. Garcia-Ruiz PJ, Chaudhuri KR, Martinez-Martin P. Non-motor symptoms of Parkinson's disease A review from the past. Journal of the Neurological Sciences 2014; 338: 30-33.
11. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord., 2002: 8(3):193-7.
12. Çakmur, R. Parkinsonizm: Klinik özelliklerine göre ayırıcı tanı ve sınıflama.
Hareket Bozuklukları Kitabı. Elibol, B. (ed.), 2011;5: 61-78.
13. Chaudhuri KR, Martinez-Martin P. Quantification of non-motor Symptoms in Parkinson’s Disease. European Journal of Neurology, 2008; (2): 2-8.
14. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain, 1991; 114: 2283-2301.
15. Jankovic, J. Pathophysiology and Clinical Assessment of Parkinsonian Symptoms and Signs. Pahwa, R., Lyons, K.E., Koller, W.C., (ed.) Handbook of Parkinson’s Disease. Marcel Dekker, Inc., New York- Basel, US.A., Switzerland, 2003; 71-107.
16. Kempster PA, Hurwitz B, Lees AJ. A new look at James Parkinson’s essay on the shaking palsy. Neurology, 2007;69:482–5.
17. Hornykiewicz O. The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm 2006; 70: 9–15.
18. Birkmayer W, Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)effect in Parkinson-akinesia. Wien Klin Wochenschr 1961;73: 787–8.
19. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism:
chronictreatment with L-DOPA. N Engl J Med 1969; 280:337–45.
20. Twelves,D., Perkins,K.S.M., Counsell,C. Systematic review of incidence studies of Parkinson's disease. 2003; 18: 19-31.
21. Taylor, K.S., Cook, J.A. , Counsell,C. Heterogeneity in male to female risk for Parkinson’s disease. Journal of Neurology Neurosurgery Psychiatry, 2007; 78; 905-906.
22. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. American journal of epidemiology. 2003; 157(11): 1015-22.
23. Adler C, Ahlkog JE. Current Clinical Practice. Parkinson‟s Disease and Movement Disorders. New Jersey. 2000; 93-113.
24. Hanağası H.A., Parkinson Hastalığında Epidemiyoloji ve Çevresel Faktörler.
Hareket Bozuklukları Kitabı. Elibol, B. (ed.), 2011; 7: 91-100.
25. Kuopio A.M., Marttila R.J.,Helenius H., Rinne U.K. Environmental risk factors in Parkinson's disease. Movement Disorders. 1999; 14: 928-939.
26. Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson's disease: A systematic review and meta-analysis. Mov Disord. 2014; 29: 1583–1590.
27. Doğu O. Parkinson hastalığının epidemiyolojisi ve risk faktörleri. Parkinson hastalığında editör Emre M. Güneş Tıp Kitap evleri, Ankara, İstanbul, 2010; 75-80.
28. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alpérovitch A, Rocca WA. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study.
European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997; 62(1):10-5.
29. Matteo R, Luigi V, Federica B, Giovanni G, Silvia R, Carlo S, Maria E, Nicola Luigi B. Prevalence of Parkinson Disease in Italy: a systematic review and meta-analysis. Acta Biomed. 2020; 91(3): e2020088.
30. Durmus H, Gokalp M.A, Hanagasi H.A, Prevalence of Parkinson’s disease in Baskale, Turkey: a population based study , Neurological Sciences. 2015 Mar;36(3):411-3.
31. Polymeropoulos MH., Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease. Science. 1997; 276: 2045-2047.
32. Klein C, Westenberger A. Genetics of Parkinson’s Disease. Cold Spring Harb Perspect Med. 2012; 2(1): a008888.
33. Ece A, Melis Ş, Ulaş A, Seray Ş, Erdem T, Cem İsmail K. Parkinson hastalığının etyopatogenezi. Deneysel tıp dergisi. 2017; 7(13): 1-23.
34. Ibanez P, Lesage S, Janin S, Lohmann E, Durif F, Deste A, Bonnet AM, Brefel-Courbon C, Heath S, Zelenika D, Agid Y, Dürr A, Brice A; French Parkinson’s Disease Genetics study group. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol. 2009
;66(1):102-8.
35. Cookson MR. Cellular effects of LRRK2 mutations. Biochem Soc Trans 2012;
40: 1070–73.
36. Martin I, Kim JW, Lee BD, et al. Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson’s disease. Cell 2014; 157: 472–
85.
37. Aasly JO, Vilariño-Güell C, Dachsel JC, et al. Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson’s disease. Mov Disord 2010; 25:
2156–63.
38. Zimprich A, Benet-Pages A, Struhal W, Graf E, Eck S.H, Offman M.N, Haubenberger D, Spielberger S, Schulte EC, Lichtner P, Rossle SC, Klopp N, Wolf E, Seppi K, Pirker W, Presslauer S, Mollenhauer B, Katzenschlager R, Foki T, Hotzy C, Reinthaler E, Harutyun A,Kralovics R, Peters A, Zimprich F, Brücke T, Poewe W, Auff E, Trenkwalder C, Rost B, Ransmayr G, Winkelmann J, Meitinger T, Strom TM. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet. 2011; 89(1): 168-75.
39. Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson’s disease:
Progress and therapeutic implications. Mov Disord 2013; 28 (1): 14-23.
40. Shulman JM, De Jager PL, Feany MB. Parkinson’s disease: genetics and pathogenesis. Annu Rev Pathol 2011; 6: 193-222.
41. Lücking CB, Dürr A, Bonifati V, et al. Association between early-onset Parkinson’s disease and mutations in the parkin gene. N Engl J Med 2000; 342:
1560–67.
42. Periquet M, Latouche M, Lohmann E, et al. Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain 2003; 126: 1271–78.
43. Bonifati V, Rohe CF, Breedveld GJ, Fabrizio E, De Mari M, Tassorelli C, Tavella A, Marconi R, Nicholl DJ, Chien HF, Fincati E, Abbruzzese G, Marini P, De Gaetano A, Horstink MW, Maat-Kievit JA, Sampaio C, Antonini A, Stocchi F, Montagna P, Toni V, Guidi M, A Dalla Libera, M Tinazzi, F De Pandis, G Fabbrini, S Goldwurm, A de Klein, E Barbosa, L Lopiano, E Martignoni, P Lamberti, N Vanacore, G Meco, B A Oostra, Italian Parkinson Genetics Network. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology. 2005; 65(1): 87-95.
44. Chu CT. A pivotal role for PINK 1 and autophagy in mitochondrial quality control: implications for Parkinson Disease. Hum Mol Genet 2010; 19: 28-37.
45. Junn E, Taniguchi H, Jeong BS, Zhao X, Ichijo H, Mouradian MM. Interaction of DJ-1 with Daxx inhibits apoptosis signal regulating kinase 1 activity and cell death. Proc Natl Acad Sci 2005; 102: 9691-9696.
46. Malgeri G, Eliezer D. Structural effects of Parkinson’s Disease linked DJ-1 mutations. Protein Sci 2008; 17: 855-868.
47. Wilson GR, Sim JC, McLean C, et al. Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathology. Am J Hum Genet 2014; 95: 729–35.
48. Puschmann A. Monogenic Parkinson’s disease and parkinsonism: clinical phenotypes and frequencies of known mutations. Parkinsonism Relat Disord 2013;
19: 407–15.
49. Schulz JB. Update on the pathogenesis of Parkinson's disease. J Neurol. 2008;
255 Suppl 5:3-7.
50. Kieburtz K, Wunderle KB. Parkinson’s disease: evidence for environmental risk factors. Mov Disord. 2013; 28: 8-13.
51. Gatto NM, Rhodes SL, Manthipragada AD, Bronstein J, Cockburn M, Farrer M, Ritz B. α-synuclein gene may interact with environmental factors in increasing risk of Parkinson’s disease. Neuroepidemiology. 2010; 35(3): 191-5.
52. Chin-Chan M, Navarro-Yepes J, Quintanilla-Vega B. Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson disease.
Front Cell Neurosci. 2015; 9: 1-22.
53. Wypijewska A, Galazka-Friedman J, Bauminger ER, Wszolek ZK, Schweitzer KJ, Dickson DW, Jaklewicz A, Elbaum D, Friedman A. Iron and reactive oxygen species activity in parkinsonian substantia nigra. Park Rel Disord 2010; 16: 329-333.
54. Noyce A, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. An Neurol. 2012; 72: 893-901.
55. Carr L, Rowell P. Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by tobacco smoke. Neuropharmacology.
1990; 29: 311-314.
56. hershey LA,Perlmutter JS. smoking and parkinson disease: where there is smoke there may not be fire. Neurology. 2014; 83(16): 1392-3.
57. Akbostancı, M. Cenk. klinik pratikte hareket bozuklukları . klinik pratikte hareket bozuklukları . ankara : güneş tıp kitapevleri , 2018.
58. Timothy J. Collier PhD. Nicholas M. Kanaan PhD. Jeffrey H. Kordower PhD.
Aging and Parkinson's disease: Different sides of the same coin? Movement disorder. 2017;32(7): 983-990.
59. Wood-Kaczmar A, Gandhi S, Wood NW. Understanding the molecular causes of Parkinson’s disease. Trends Mol Med. 2006; 12 (11): 521-528.
60. Ma SY, Roytt M, Collan Y, Rinne JO. Unbiased morphometrical measurements show loss of pigmented nigral neurones with ageing. Neuropathology and Applied Neurobiology. 1999; 25: 394-399.
61. Rodriguez M, Rodriguez-Sabate C, Morales I, Sabate M. Parkinson’s disease as a result of aging. Aging Cell. 2015; 14 (3): 293-308.
62. Marras, C. ; Tanner , C.M. Epidemiyology of Parkinson’s disease. Neurologic Principles and Practice (2nd ed). Movement Disorders. 2004; 177-95.
63. Masters CL, Kril JJ, Halliday GM, et al. Overview and recent advances in neuropathology. Part 2: Neurodegeneration. Pathology 2011; 43: 93–102.
64. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E.
Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003; 24: 197–211.
65. Wang B, Abraham N, Gao G, Yang Q. Dysregulation of autophagy and mitochondrial function in Parkinson's disease. Transl Neurodegener. 2016; 5: 19.
66. Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson’s disease: molecular mechanisms and pathophysiological consequences.
The EMBO Journal. 2012; 31(14): 3038-62.
67. Moon HE, Paek SH. Mitochondrial dysfunction in Parkinson’s disease.
Experimental Neurobiology. 2015; 24 (2): 103-116.
68. Dolle C, Flønes I, Nido G S, Miletic H, Osuagwu N, Kristoffersen S, Lilleng PK, Larsen J,- Tysnes OB, Haugarvoll K, Bindoff LA. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nat Commun. 2016;
7: 13548.
69. Haytural H, Tüzün E. Parkinson hastalığı’nın hayvan modelinde PI3K/Akt yolağı ile mitokondriyal, oksidatif ve apoptotik parametrelerin ilişkisi. Deneysel Tıp Araştırma Enstitüsü Dergisi. 2013; 3 (7): 28-37.
70. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford University. 2015.
71.Youdim MB, Riederer P. Understanding Parkinson’s disease. Sci Am. 1997; 276 (1): 38-45.
72. Zheng Q, Huang T, Zhang L, Zhou Y, Luo H, Xu H, Wang X. Dysregulation of Ubiquitin- Proteasome System in Neurodegenerative Diseases. Frontiers in Aging Neuroscience. 2016; 8: 303.
73. Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol. 1988; 75: 345–353.
74. Xiong H, Wang D, Chen L, Choo YS, Ma H, Tang C, Xia K, Jiang W, Ronai Z, Zhuang X, Zhang Z. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest. 2009; 3 (119): 650-660.
75. Nagatsu T, Sawada M. Inflammatory process in Parkinson’s disease: Role for cytokines. Curr Pharm Des. 2005; 11(8): 999-1016.
76. Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, Joong Lee S, Masliah E, Hwang D, Lee HJ, Lee SJ. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Communic.
2013; 4: 1562.
77. Cicchetti F, Brownell AL, Williams K. vd. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci. 2002;
15(6): 991-8.
78. Sita G, Hrelia P, Tarozzi A, Morroni F. Isothiocyanates Are Promising Compounds against Oxidative Stress, Neuroinflammation and Cell Death that May Benefit Neurodegeneration in Parkinson’s Disease. Int J Mol Sci. 2016; 17(9):
1454.
79. Abramov AY and Duchen MR. Mechanisms underlying the loss of mitochondrial membrane potential in glutamate excitotoxicity. Biochimica et Biophysica Acta. 2008; 1777 (7- 8): 953-964.
80. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986; 9:
357-81.
81. Gerfen CR. Molecular effects of dopamine on striatal-projection pathways.
Trends Neurosci. 2000; 23(10 Suppl): 64-70.
82. Zileli T, Baysal Aİ. Nöroanatomi-Nörofizyoloji esasları. Hacettepe Ünv.
Yayınları B32 Ankara, 1989;10-15.
83. Nambu A, Tokuno H, Takada M.Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res. 2002. 43(2): 111-7.
84. Daniela Berg , Ronald B Postuma , Charles H Adler ,Bastiaan R Bloem , Piu Chan , Bruno Dubois , Thomas Gasser , Christopher G Goetz , Glenda Halliday , Lawrence Joseph , Anthony E Lang , Inga Liepelt-Scarfone , Irene Litvan, Kenneth Marek , José Obeso , Wolfgang Oertel, C Warren Olanow, Werner Poewe, Matthew Stern, Günther Deuschl. MDS research criteria for prodromal Parkinson's disease.
Mov Disord. 2015; 30(12):1600-11.
85. Zetusky WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson's disease:
clinical and prognostic implications. Neurology. 1985; 35(4): 522-6.
86. Shahed J, Jankovic J. Motor symptoms in Parkinson's disease. Handb Clin Neurol. 2007; 83: 329-42.
87. Rao G, Fisch L, Srinivasan S, D'amico F, Okada T, Eaton C et al. Does this patient have Parkinson disease?. JAMA. 2003; 289(3): 347-53.
88. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality.
Neurology. 1967; 17(5): 427-42.
89. Ebersbach G, Baas H, Csoti I, et al. Scales in Parkinson’s disease. J Neurol.
2006; 253: 32–5.
90. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988; 51: 745–52.
91. Tarakad A, Jankovic J. Diagnosis and Management of Parkinson's Disease.
Semin Neurol. 2017; 37(2): 118-126.
92. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015; 30(12): 1591-601.
93. Bagheri H, Damase-Michel C, Lapeyre-Mestre M, et al. A study of salivary secretion in Parkinson’s disease. Clin Neuropharmacol. 1999; 22: 213–15.
94. Kızıltan, Güneş. Parkinson Hastalığının Hareketle İlişkili ve İlişkisiz Belirti ve Bulgular. Hareket Bozuklukları Kitabı. Elibol, B. (ed.), 2011; 9: 113-128.
95. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 1993; 50(2): 140-8.
96. Shulman LM, Singer C, Bean JA, et al. Internal tremor in patients with Parkinson’s disease. Mov Disord. 1996; 11: 3–7.
97. Shahed J, Jankovic J. Exploring the relationship between essential tremor and Parkinson’s disease. Parkinsonism Relat Disord. 2007; 13: 67–76.
98. Broussolle E, Krack P, Thobois S, et al. Contribution of Jules Froment to the study of parkinsonian rigidity. Mov Disord. 2007; 22: 909–14.
99. DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science. 2003; 302: 830-834.
100. Bloem BR. Postural instability in Parkinson’s disease. Clin Neurol Neurosurg.
1992; 94: 41–5.
101. Bloch A, Probst A, Bissig H, Adams H, Tolnay M. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol. 2006; 32(3): 284-95.
102. Ashour R, Tintner R, Jankovic J. Striatal deformities of the hand and foot in Parkinson’s disease. Lancet Neurol. 2005; 4: 423–31.
103. Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord. 2006;
21: 1856–63.
104. Chaudhuri KR, Tolosa E, Schapira A, Poewe W ;Parkinson Hastalığının Non-motor Semptomları (Non-Non-motor Symptoms of parkinson's disease); Oxford; Çeviri Editörü M Cenk Akbostancı, Sigma Yayıncılık, 2011.
105. Stacy M, Bowron A, Guttman M, et al. Identification of motor and non motor wearing-off in Parkinson’s disease: comparison of a patient questionnaire versus clinician assessment. Mov Disord. 2005; 20: 726 –733.
106. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, MacPhee G, MacMahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Yogini Naidu, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, and Schapira AH . The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord.
2007; 22(13): 1901-11.
107. O’Sullivan SS, Williams DR, Gallagher DA, et al. Non-motor symptoms as presenting complaints in Parkinson’s Disease : a clinicopathological study. Mov.
Disord 2008; 23:101-6.
108. Abbot RD, Petrovich H, White LR, et al. Frequency of bowel movements and the future risk of Parkison’s Disease Neurology. 2001; 57: 456-62.
109. Ueki A, Otsuka M , Life style risks of Parkinson’s Disease: association between decreased water intake and constipation. J Neurol. 2004; 251(suppl 7):
vII18-23.
110. Bronner G, Royter V, Korcyzn AD, Giladi N, Sexual Disfunction in Parkinson’s Disease. J Sex Marital Ther. 2004; 30: 95-105.
111. Verbaan D, Marinus J, Visser M, et al. Patient-reported autonomic symptoms in Parkinson disease. Neurology. 2007; 69(4): 333-41.
112. Braune S, Reinhardt M, Schnitzer R, et al. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology. 1999.
53(5): p 1020-5.
113. Hirayama M. Sweating dysfunctions in Parkinson's disease. J Neurol. 2006;
253(7): 42-47.
114. Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep. 2002; 25(2): 120-38.
115. Askenazy JJ. Sleep disturbances in Parkinsonism. J Neural Transm (Vienna).
2003; 110: 125-50.
116. Iranzo A, Molinuevo JL, Santamaria J, et al REM sleep behaviour disorder as an early marker for a neurodegenerative disorder : a descriptive study. Lancet Neurology. 2006; 5: 572-7.
117. Boeve BF, Silber MH, Saper CB, et al. Pathophysiology of REM sleep behavious disorder and relevance to neurodegenerative disease, Brain. 2007; 130:
2770-88.
118. Kaynak D, Kiziltan G, Kaynak H, Benbir G, Uysal O. Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment. Eur J Neurol. 2005; 12(3): 199-207.
119. Gjerstad MD, Aarsland D, Larsen JP.Development of daytime somnolence over time in Parkinson's disease. Neurology. 2002; 58(10): 1544-6.
120. Ondo W, Jankovic J. Restless legs syndrome: clinicoetiologic correlates.
Neurology. 1996; 47(6): 1435-41.
121. Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol. 1982; 39(11): 739.
122. Banno K, Delaive K, Walld R, Kryger MH. Restless legs syndrome in 218 patients: associated disorders. Sleep Med. 2000; 1(3): 221-229.
123. Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson’s Disease and Restless Legs Syndrome. Arch Neurol. 2002; 59: 421-4.
124. Montplaisir J, Boucher S, Poirier G, et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997; 12(1): 61-5.
125. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson’s Disease: A case-control study. Mov. Disord. 2000;
15 (4): 669-77.
126. Ishihara L, Briane C. A systematic review of depression and mental illness preceding Parkinson’s Disease. Acta Neurol Scand. 2006; 113: 211-20.
127. Leentjens AF, Van den Akker M, Medsmakers JF, et al. Higher incidence of depression preceding the onset of Parkinson’s disease: A register study. Mov Disord 2003; 18; 414-8.
128. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999; 67(4):
492-6.
129. Williams-Gray CH, Foltynie T, Brayne CE, et al. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain. 2007; 130(7): 1787-98.
130. Lees AJ, Smith E, Cognitive deficits in the early stage of the Parkinson’s Disease Brain 1983; 106: 257-70.
131. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;
60(3): 387-92.
132. Reijnders JS, Ehrt U, Lousberg R, et al. The association between motor subtypes and psychopathology in Parkinson's disease.Parkinsonism Relat Disord.
2009; 15(5): 379-82.
133. Kupsky WJ, Grimes MM, Sweeting J, et al. Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells.
Neurology. 1987; 37(7): 1253-5.
134. Koller WC. Sensory symptoms in Parkinson's disease. Neurology. 1984;
34(7): 957-9.
135. Nègre-Pagès L, Regragui W, Bouhassira D, et al; DoPaMiP Study Group.
Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey.
Mov Disord. 2008; 23(10): 1361-9.
136. Christopher G Goetz, Gian Pal. Initial management of Parkinson’s disease.
BMJ
. 2014; 349: g6258.
137. Çakmur R. Hareket Bozuklukları Tanı ve Tedavi Rehberi. Parkinson Hastalığında Tedavi. 2018: 54-83.
138. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA.
2000; 284(15): 1931-8.
139. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord. 2006; 21(3): 343-53.
140. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease
who were treated with ropinirole or levodopa. N Engl J Med. 2000; 342(20): 1484-91.
141. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Archives of neurology. 2006; 63(12): 1756–60.
142. Pogarell O, Gasser T , van Hilten JJ , et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002; 72(6):
713-20.
143. Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I ve 1427-9., Parkinson Study Group TEMPO and PRESTO Investigators. Safety of rasagiline in elderly patients with Parkinson disease. Neurology. 2006; 66(9): 1427-9.
144. Warren Olanow, M.D., Olivier Rascol, M.D., Ph.D., Robert Hauser, M.D., the ADAGIO Study Investigators*A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson disease. N Engl J Med. 2009; 361: 1268-1278.
145. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002; 59(12): 1937-43.
146. Shoulson I, Oakes D, Fahn S, et al; Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002; 51(5): 604-12.
147. Lakshmi Nayak, Claire Henchcliffe..Rasagiline in treatment of Parkinson’s disease. Neuropsychiatr Dis Treat. 2008; 4(1): 23–32.
148. Rajput AH, Uitti RJ, Lang AE, Rajput AH, Kumar R, Galvez‐Jimenez N.
Amantadine ameliorates levodopa induced dyskinesia. Neurology. 1997; 48: 328.
149. Calabresi P, Di Flippo M, Ghiglieri V, Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesi. Mov Disord. 2008; 23 Suppl 3: 570-9.
150. Thomas A, Iacona D, Luciano AL, Armellino K, Di Ioiro A,Onofrj M.
Duration of amantadine benefit on dyskinezia of severe parkinson's disease. J Neurol Neurosurg Psychiatr 2004; 75: 141-143.
151. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev.
2003; (2): CD003735.
152. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, Larsen JP, Lees A, Oertel W, Poewe W, Rascol O, Sampaio C; European Federation of Neurological Movement Disorder Society-European Section. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol. 2006; 13(11): 1170-85.
153. Ossig C, Reichmann H. Treatment strategies in early and advanced Parkinson disease. Neurol Clin. 2015; 33(1): 19-37.
154. Defer GL, Widner H, Marié RM, Rémy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD).
Mov Disord. 1999; 14(4): 572-84.
155. W M Michael Schüpbach , Jörn Rau, Jean-Luc Houeto, Paul Krack, Alfons Schnitzler, Carmen Schade-Brittinger, Lars Timmermann, Günther Deuschl. Myths and facts about the EARLYSTIM study. Mov Disord. 2014; 29(14): 1742-50.
156. Tiago A Mestre , Alberto J Espay, Connie Marras, Mark H Eckman, Pierre Pollak, Anthony E Lang. Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better. Mov Disord. 2014; 29(14): 1751-6.
157. Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain. 2008; 131: 2720-8.
158. Ostergaard L, Werdelin L, Odin P, et al. Pen injected apomorphine against off
158. Ostergaard L, Werdelin L, Odin P, et al. Pen injected apomorphine against off